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Conclusions & Future Directions
Epstein-Barr virus (EBV) infects at least 90% of the global adult 
population.1  In addition to causing infectious mononucleosis, 
EBV is associated with many types of cancers, including Burkitt 
lymphoma, nasopharyngeal carcinoma, and Hodgkin 
lymphoma.2 Preventing EBV infection would therefore have an 
enormous impact on public health, but despite several 
preclinical trials, a vaccine against the virus has not yet been 
licensed for use in humans.  EBV vaccine research thus far has 
focused on the resulting neutralizing antibody response because 
its clinical and protective benefits are well-established.3  
However, the vaccine’s ability to induce a memory T cell 
response has not been reported on in detail.  Investigation in 
this area is needed to better understand the efficacy and safety 
of an EBV-gp350 vaccine.  The findings of this ongoing project 
will help our laboratory make progress towards developing a 
vaccine that is suitable for human use. 
Mice
6- to 8-week old C57BL/6 mice were housed under specific 
pathogen-free conditions at the University of Minnesota Cancer and 
Cardiovascular Research Building, and all experiments were 
conducted according to federal and institutional guidelines under 
approved Institutional Animal Care and Use Committee protocols.
Immunization
5 mice were injected with 5 ug gp350 + 5 ug GLA/SE adjuvant, and 
5 mice were injected with 5 ug GLA/SE only.  Booster injections 
were administered after one month. 
gp350 tetramer
Phycoerythrin (PE)- and allophycocyanin (APC)-conjugated pMHCII
tetramers containing the gp350 peptide EIPEFPFYPTCNVCT were 
produced and provided by Dr Marc Jenkins of the University of 
Minnesota’s Department of Microbiology and Immunology. 
Data Collection
Ten days after receiving the booster, immunized mice were injected 
with 200 ug of gp350 peptide.  Two hours after the exposure, the 
spleen and inguinal lymph nodes were harvested.4 Samples were 
then stained with the tetramer in addition to fluorescence-
conjugated antibodies specific for CD44, a memory CD4+ T cell 
marker, and IFN-y, a marker for their activity.4
Fluorescence-Activated Cell Sorting (FACS)
Samples were run on an LSR II flow cytometer with 14 fluorescent 
parameter capability.  Irrelevant tetramer and isotype control 
antibodies were used to measure non-specific background staining.
Data Analysis
Data was analyzed using FlowJo software.  The number of anti-
gp350 CD4+ T cells was determined by gating on live CD4+ CD44+






The aim of this study was to establish a profile of the anti-gp350 
CD4+ T cell response in mice receiving an EBV-gp350 + GLA/SE 
vaccine.  We expected to observe an increase in the number and 
activity of gp350-specific CD4+ memory cells in vaccinated mice.
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Figure 1. Flow cytometry plots of the indicated molecules for live CD4+ T cells from spleen 
samples from mice that were or were not injected with gp350 peptide two hours before 
collection and analysis.
Figure 2. Flow cytometry plots live CD4+ CD44+ T cells from spleen samples from mice that were 
or were not injected with gp350 peptide two hours before collection and analysis.
Figure 3. MHC class II tetramer technology as a method for detecting antigen-specific CD4+ T cells. 
Immunized mouse spleen
EBV-gp350 iv., 10 days after booster
• We observed a high background signal from the IFN-y assay 
(Figure 1). To minimize this in future trials, we will reduce the 
duration of incubation with the anti-IFN-y antibody.
• Few of the CD44+ CD4+ T cells detected were bound to the PE-
and APC-conjugated tetramers.  This suggests that we need to 
optimize our tetramer staining and detection assay.
• CD4 enrichment
• Tetramer-based enrichment
• Performing an experiment with a different peptide-tetramer 
pairing to demonstrate proof-of-concept
• We can try to maximize the memory CD4+ T cell number and 
activity detected by harvesting spleen and lymph node samples 
earlier than 10 days post-booster.
• While these challenges prevent us from making confident 
conclusions, the preliminary data suggest a higher specific 
memory CD4 T cell response in immunized mice.
• When our assay is optimized, we will further characterize 
phenotype and activity by looking at:
• Surface molecules CXCR5, CXCR3, and CX3CR1
• Intracellular molecules Bcl-6, T-bet, and ROR𝛾T
